ArticleEye (London, England)2024
Sustained disease control with aflibercept 8 mg: a new benchmark in the management of retinal neovascular diseases.
Article in Eye (London, England), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Aflibercept 8 mg for diabetic macular edema and neovascular age-related macular degeneration: an italian expert consensus paper.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2026Article
- Switching to aflibercept 8 mg in neovascular age-related macular degeneration: real-world outcomes according to switch indication.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2026Article
- Early real-world outcomes of aflibercept 8 mg in previously treated neovascular age-related macular degeneration.Eye (London, England) · 2026Article
- Retinal vein occlusion-related macular edema: An updated review of current evidence and future directions.Indian journal of ophthalmology · 2026Review
- Comparative Clinical and Therapeutic Landscape of Aflibercept Biosimilars (YESAFILI), High-Dose Aflibercept 8 mg (EYLEA HD), and Faricimab (VABYSMO): A Structured Narrative Review.Clinical ophthalmology (Auckland, N.Z.) · 2026Review
- Early Real-World Outcomes of Switching to 8 mg Aflibercept for Neovascular Age-Related Macular Degeneration in the United Kingdom.Life (Basel, Switzerland) · 2025Article
- Early real-world outcomes of intravitreal aflibercept 8 mg in treatment-Naïve neovascular AMD: AI-assisted fluid volume analysis.International journal of retina and vitreous · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.